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Abstract 
Most uninfected children born to diagnosed HIV-infected women in the United 
Kingdom (UK) are exposed to antiretroviral therapy (ART) in utero and neonatally, and 
concerns exist about potential adverse effects of such exposure. We explored the 
feasibility of using national clinic-based follow-up to investigate the association 
between ART exposure and adverse health events occurring after the neonatal period. 
 
Active surveillance of obstetric and paediatric HIV infection is conducted through the 
National Study of HIV in Pregnancy and Childhood (NSHPC). Between 2002 and 2005, 
health professionals enrolled previously notified uninfected children in a consented 
follow-up study (the CHART study). Follow-up information was collected 
opportunistically using a standard questionnaire. 
 
Of 2104 eligible uninfected children born in the UK between 1996 and 2004, 704 
(33.5%) were enrolled in CHART; parents of 4.8% (100/2104) declined, 2.8% 
(59/2104) had gone abroad, 21.6% (455/2104) were not contactable, and the remaining 
37.3% (786/2104) were not enrolled mainly because of lack of clinic resources or 
unwillingness of health professionals to approach the families.  
 
Demographic characteristics and type of ART exposure for enrolled and non-enrolled 
children were similar. Latest information on enrolled children was available at a median 
age of 24 months. Minor childhood ailments were reported in the majority of children, 
febrile seizures in 1.6% (11/704), and major health problems in 3.8% (27/704). It was 
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reassuring that prevalence of these outcomes was within UK norms, but numbers were 
small and duration of follow-up was limited.  
 
The difficulties encountered in enrolling and retaining children in this study indicate 
that comprehensive clinic-based follow-up of ART-exposed uninfected children is not 
practical. Alternative approaches are required; a robust, secure data linkage protocol 
would provide a more feasible and sustainable system for long term monitoring of in 
utero ART exposure. 
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Introduction 
Use of antiretroviral therapy (ART), elective caesarean section and avoidance of breast 
feeding have led to a reduction in mother-to-child HIV transmission (MTCT) rates in 
resource-rich settings from around 20% to less than 2% (European Collaborative Study, 
2005b; Magder et al., 2005; Townsend et al., 2008a). In 2006, over 95% of HIV-
infected pregnant women delivering in the UK were diagnosed prior to delivery (The 
UK Collaborative Group for HIV and STI Surveillance, 2007), and over 95% of these 
were prescribed ART either to reduce the risk of MTCT or for their own health 
(Townsend et al., 2008a). These developments, along with the increased prevalence of 
HIV infection in pregnant women in the UK, which doubled between 2001 (0.11%) and  
2006 (0.23%) (The UK Collaborative Group for HIV and STI Surveillance, 2007), 
contributed to an increase in the number of ART-exposed uninfected infants from about 
390 in 2001 to about 1100 in 2006 (NSHPC data).  
 
There are potential short- and long-term risks associated with ART exposure in utero 
and in early life (Thorne & Newell, 2005). The teratogenic nature of some antiretroviral 
drugs has been demonstrated in animal studies (Public Health Service Task Force, 
2007b), though large studies in humans have not found an association between ART 
exposure and prevalence of congenital abnormalities (Antiretroviral Pregnancy Registry 
Steering Committee, 2007; European Collaborative Study, 2005a; Thorne & Newell, 
2005; Townsend et al., 2006a). Antiretroviral drugs in the nucleoside reverse 
transcriptase inhibitor (NRTI) class are known to deplete mitochondrial DNA and in 
1999 eight ART-exposed uninfected children born in France were reported with 
persistent mitochondrial dysfunction, two of whom died (Blanche et al., 1999). 
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However a review of mortality in more than 20,000 children in five US cohorts did not 
identify any deaths associated with mitochondrial dysfunction (The Perinatal Safety 
Review Working Group, 2000). The French group also reported that exposure to ART 
was associated with febrile seizures in children under 18 months of age (Landreau-
Mascaro et al., 2002). As NRTIs become incorporated into host DNA, there is potential 
for long-term carcinogenic effects; tumours have been observed in mice after in utero 
exposure to zidovudine (Olivero et al., 1997; Poirier et al., 2004), but long-term data on 
humans exposed to zidovudine and other antiretroviral drugs in utero are lacking.  
 
While national guidelines recommend that children exposed to antiretroviral drugs are 
monitored over the long term, practical standard protocols have not been developed 
(Public Health Service Task Force, 2007a). In order to assess the feasibility of national 
clinic-based follow-up in the UK, the CHildren exposed to AntiRetroviral Therapy 
(CHART) study was conducted between 2002 and 2005. Eligible children were 
identified from reports to the national programme for obstetric and paediatric HIV 
surveillance, the National Study of HIV in Pregnancy and Childhood (NSHPC) 
(Townsend et al., 2008b). 
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Methods 
The core surveillance mechanisms of the NSHPC include two active reporting schemes. 
Pregnancies in HIV-infected women are reported to the NSHPC in association with the 
Royal College of Obstetricians and Gynaecologists. Children with HIV infection and 
infants born to HIV-infected women are reported through the British Paediatric 
Surveillance Unit of the Royal College of Paediatrics and Child Health (Nicoll et al., 
2000) or directly to the NSHPC. Respondents provide information on demographic 
characteristics, HIV-related laboratory investigations, ART use and perinatal outcomes. 
Live births reported through the obstetric scheme are linked with paediatric reports 
using demographic information, as names are not collected. Paediatric cases are 
followed up to establish HIV infection status and once a child is confirmed uninfected, 
routine surveillance ceases. Individual patient consent is not required for case 
notification to the NSHPC and surveillance staff contact is exclusively with health care 
respondents not patients.  
 
Uninfected children born in the UK and reported to the NSHPC were eligible for 
enrolment in CHART. The notifying paediatric respondent was asked to approach the 
child’s family to explain the study and seek consent. If the paediatric respondent 
thought it more appropriate, an alternative health professional aware of the mother’s 
HIV infection, such as a genitourinary (GU) physician or general practitioner (GP), was 
contacted to do this.  
 
Enrolment of children born between 1996 and 2000 commenced in April 2002 in 11 
hospitals (seven in London, one each in Birmingham, Leicester, Oxford, Sheffield) 
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selected on the basis of the number of UK-born uninfected children reported to the 
NSHPC (>40% of all reports between 1996 and 2000 were from these 11 hospitals). 
From January 2003 the study was extended beyond the pilot phase to include all 
uninfected children born between January 2001 and April 2004 in the UK. Enrolment 
ceased in June 2005 and data collection in August 2005.  
 
A study information sheet was provided for health professionals and families. 
Prospectively collected surveillance data, including demographic and perinatal details 
and information on ART exposure and laboratory investigations was available through 
the NSHPC. Health professionals completed a short annual CHART questionnaire for 
each enrolled child, in consultation with parents or carers. This questionnaire was 
designed to identify children with serious health or developmental problems: data 
collected included height and weight, perceived problems with movement, speech, 
hearing, sight or behaviour, and details of hospital admissions, specialist referrals or 
ongoing medication. We worked closely with the health professionals and they provided 
feedback on the process of study enrolment, follow-up, and the difficulties they 
encountered. 
 
Data were managed using Microsoft Access 2002 and analysed using SAS (version 9.1, 
SAS Institute, Cary, NC, USA). Univariable comparisons were tested with χ2 tests and t 
tests.  
 
Both the NSHPC and CHART were approved by the Great Ormond Street Hospital for 
Children NHS Trust / Institute of Child Health Research Ethics Committee at 
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commencement, and subsequently by the London Multi-centre Research Ethics 
Committee in 2004 (MREC/04/2/009 and 04/MRE02/47 respectively).  
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Results 
Enrolment in CHART 
The 2104 eligible children were reported from 168 hospitals. By the end of the study 
period 33.5% (704/2104) of children had been enrolled (Figure 1). Of those enrolled, 
23.6% (166/704) were subsequently lost to follow-up during the study period and the 
parents of another 1.8% (13/704) withdrew from the study.  
[insert Figure 1] 
 
Parents of 4.8% (100/2104) of eligible children declined enrolment because of concerns 
about confidentiality, difficulty in accepting their own HIV diagnosis, or the 
inconvenience of participating. Another 2.8% (59/2104) of children had left the UK and 
two children had died: one with congenital tuberculosis and one sudden infant death 
(drug withdrawal symptoms at birth, exposed to zidovudine in utero). Two percent 
(44/2104) were excluded because health professionals considered it inappropriate to 
contact the family (for example because the mother had died, or because of conflict 
within the family) or could not identify the child from the available information. A 
further 21.6% (455/2104) were lost to follow-up because the family had moved or no 
longer attended the clinic, and health professionals were still trying to contact the 
families of 11.1% (233/2104) when the study ended. Seven paediatric respondents, 
responsible for 10.9% (230/2104) of eligible children, declined to participate in the 
study, mainly citing lack of clinic resources. The paediatric contacts who had notified 
the remaining 13.2% (277/2104) of children made no response, despite reminders. 
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Families were generally approached about CHART when the child attended clinic for 
their confirmatory negative antibody test at 12 to 18 months of age. In some cases the 
approach was by telephone, home visit or letter.  
 
In feedback some health professionals reported that they needed to offer more clinic 
appointments or spend more time with parents discussing ART exposure because of 
CHART. Patient loss to follow-up and a lack of resources were frequently mentioned as 
factors that made involvement in the study difficult; a selection of health professionals’ 
comments is shown in Table 1. 
 
[insert Table 1] 
 
Characteristics of children eligible for CHART 
Of the eligible children, 75.7% (1566/2069) had mothers born in sub-Saharan Africa 
and 17.3% (358/2069) in Europe (Table 2). Injecting drug use was the probable HIV 
risk factor for the mothers of 2.7% (53/1998) of children, while 85.7% (1713/1998) 
probably acquired infection in countries with generalised HIV epidemics. Median 
maternal age at delivery was 30 years (range 15-53). Altogether 95.0% (1981/2085) of 
children were exposed to ART in utero, 74.4% (1473/1981) of these to highly active 
antiretroviral therapy (HAART). 
 
Enrolled and non-enrolled children were similar in terms of maternal region of birth 
(χ2=1.89, p=0.389), maternal HIV risk factor (χ2=2.79, p=0.248) and in utero ART 
exposure (χ2=8.70, p=0.069) (Table 2). Enrolled children were born to slightly older 
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mothers (mean maternal age 30.5 vs 29.5 years, t=-3.79, p<0.001). Congenital 
abnormalities were reported in 3.0% (63/2104) of eligible children and there was no 
significant difference in prevalence between enrolled (3.3%, 23/704) and non-enrolled 
children (2.9%, 40/1400) (χ2=0.27, p=0.603). Information on gestational age was 
available for 1661 infants, of whom 16.6% (275/1661) were born prematurely (<37 
weeks gestation); the prematurity rate did not differ by enrolment status (χ2=0.58, 
p=0.448). Median age at last reported contact for non-enrolled children (reported on 
NSHPC paediatric forms) was 6 months (range 1-45), and for enrolled children, median 
age at last contact in CHART was 24 months (range 5-106). 
 
[insert Table 2] 
 
Enrolled children 
Of the 704 enrolled children, 76.7% (540/704) had one CHART questionnaire 
completed, 21.0% (148/704) two and 2.3% (16/704) three. Most of the 884 
questionnaires were completed by paediatric nurses (58.1%, 514/884) or paediatricians 
(34.3%, 303/884) and the remainder by GU physicians, GU nurses, GPs or midwives. 
Three-quarters were completed in clinic (76.1%, 673/884) and in most cases the child 
was present (82.0%, 552/673).  
 
No health or developmental problems were reported for 37.5% (264/704) of children. 
Childhood infections and other common conditions were reported for 57.1% (402/704); 
these included chest infections and colds (201), gastroenteritis (28), wheezing/asthma, 
eczema or other allergies (93), speech problems or speech delay (50) and other minor 
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developmental or behavioural problems (63). Some children had more than one minor 
condition reported.  
 
Febrile seizures were reported in 1.6% (11/704) of children and a variety of other 
significant health problems or conditions (details shown in Table 3) in another 3.8% 
(27/704). Seventy-four percent (28/38) of these children were exposed to HAART in 
utero, similar to the exposure rate in all enrolled children (72.0%, 503/704). Altogether, 
60 (8.5%) of the 704 enrolled children were reported to have been admitted to hospital 
on at least one occasion. 
 
[insert Table 3] 
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Discussion  
Despite substantial input from paediatricians, clinical nurse specialists and other health 
professionals looking after HIV-affected families, we experienced considerable 
difficulty enrolling and retaining children in this study. Only a third of about 2100 
eligible children were enrolled, of whom about a quarter were subsequently lost to 
follow-up within the three-year study period. Because we had no direct contact with 
families we relied on local clinic staff, but in many cases they had lost touch with 
families, lacked the time and resources to participate fully in the study, or because of 
staff turnover were unfamiliar with the families and reluctant to make contact.  
 
Similar difficulties in recruiting HIV-exposed uninfected children have been reported 
from the Perinatal AIDS Collaborative Transmission Study – HIV Follow-up Of 
Perinatally Exposed Children (PACTS-HOPE). In this US study only 22% (180/819) of 
eligible uninfected children were recruited over a two-year period, despite direct contact 
with families and relatively low turn over of health care staff (Freedman et al., 2006). 
Comparable attrition rates to those experienced in CHART were reported from the 
Pediatric AIDS Clinical Trials Group (PACTG) 219 study, a long-term observational 
study of children enrolled in the 076 trial, where about 10% were lost to follow-up each 
year (Culnane et al., 1999). 
 
The number of uninfected ART-exposed infants born each year substantially increased 
over the study period due to the increasing prevalence of HIV infection in pregnant 
women from 2000 onwards (The UK Collaborative Group for HIV and STI 
Surveillance, 2007) together with the successful implementation of routine antenatal 
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HIV testing and high uptake of interventions, including ART (Townsend et al., 2006b). 
Early in the HIV epidemic, most affected families in the UK lived in or close to 
London, but this situation has changed in recent years with the proportion of 
pregnancies reported to the NSHPC from outside London increasing from 13% in 
1997/9 to 43% in 2004/6 (Townsend et al., 2008b). Consequently there has been an 
increase both in the number of HIV-exposed uninfected children reported per unit, and 
the number of units reporting cases over time. Many out-of-London units caring for 
eligible children had no nominated paediatric HIV staff or integrated “family clinic” 
(Sharland et al., 2003). This is likely to have contributed to the lower rates of enrolment 
when the study was extended from the initial 11 units (births 1996-2000) to include all 
UK births (2001-2004); lack of clinic resources was a common problem cited by 
respondents (see Table 1). 
 
Since confirmatory tests to exclude HIV infection can now be carried out within three 
months of birth (in the absence of a continuing risk through breastfeeding) (Hawkins et 
al., 2005), families do not necessarily have an incentive to continue contact with the 
paediatric clinic. Paediatric respondents not in continuing contact with families were 
understandably cautious about approaching GPs and health visitors, in case they were 
not aware of the family’s HIV status. 
 
Our ability to draw conclusions from this study about the safety or otherwise of ART 
exposure is limited. While it was reassuring that enrolled and non-enrolled children 
were similar in terms of their baseline demographic characteristics and ART exposure, 
numbers were small and the follow-up period was short. It was not possible to identify 
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and enrol an appropriate control group with comparable ethnic make-up and maternal 
chronic disease levels within the scope of this study. Unexposed infants born to 
diagnosed women were not a suitable control group since diagnosed women who do not 
take ART antenatally are likely to differ systematically from those who do (for example, 
having declined treatment, been diagnosed very close to delivery, or delivered very 
prematurely) (Townsend et al., 2007). In fact only 5% of eligible children, and only 3% 
of the enrolled group, were not exposed antenatally.  
 
In the absence of a formal control group we compared reported health outcomes in the 
enrolled children with those of the UK Millennium Cohort Study (MCS), a cohort study 
of approximately 18,800 babies born in 2000 and 2001, in which children from 
disadvantaged and ethnic wards were over-sampled. MCS parents reported prevalence 
rates for chest infections (29%), wheezing or asthma (6%) and hospitalisation (13-15%) 
among infants by nine months of age (Dezateux et al., 2005); these compare with 
reported prevalence rates in CHART of 29%, 7% and 9% respectively at a median age 
of 24 months. In the population of HIV-exposed children born in the UK and Ireland, no 
association has been detected between ART exposure and congenital abnormalities 
(Townsend et al., 2006a); the reported prevalence of congenital abnormalities in the 
CHART children was within UK population parameters of 2-3% for major 
abnormalities (Boyd et al., 2005), as was that of febrile seizures.  
 
Earlier routine enrolment of families into follow-up could have eased some of the 
problems encountered in this study; however, the overall increasing number of 
uninfected children, lack of staff resources, parental concerns about confidentiality, and 
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the continuing attrition of enrolled children because of family mobility were also 
substantial barriers to recruitment and retention. Issues of confidentiality and lack of 
staff resources were also raised in a survey of parents’ and health professionals’ views 
on the acceptability of different ways to monitor ART-exposed children over the longer 
term (Hankin et al., 2007a). Our experience indicates that consented opportunistic 
clinic-based follow-up is not a practical approach for monitoring ART-exposed 
uninfected children in the UK over the long term, and alternative strategies need to be 
developed. Paediatric reports to the NSHPC are now linked to routine cancer and death 
data collected by the Office for National Statistics for long term monitoring; although 
this approach is limited to specific outcomes, it demonstrates the feasibility and 
potential of data linkage (Hankin et al., 2007b).  
 
HIV-infected pregnant women are taking increasingly complex drug regimens at all 
stages of pregnancy, including at conception, and the number of exposed uninfected 
children is rising rapidly. A robust, secure data linkage protocol for monitoring their 
long-term health must be developed within an appropriate ethical framework which 
acknowledges that they might not be aware, as adults, of their exposure. Concerns about 
consent, confidentiality and disclosure of maternal HIV status to health professionals 
and the uninfected child must be considered alongside potential longer term benefits. If 
unexpected late onset adverse outcomes were identified, for example in relation to 
growth, aging or reproduction, this could guide changes in HIV treatment guidelines, or 
inform screening or treatment of ART-exposed individuals. Similar situations have 
occurred in the past, for example with prenatal exposure to diethylstilboestrol (Royal 
College of Obstetricians and Gynaecologists, 2007; Troisi et al., 2007). Such a protocol 
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could potentially be extended or adapted to cover other sensitive prenatal or perinatal 
exposures, for example assisted reproduction, treatment for ambiguous genitalia, or 
other drug treatments.  
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